Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.17USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$8.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
158,472
52-wk High
$14.00
52-wk Low
$4.10

Select another date:

Wed, Sep 26 2018

Judge disqualifies prosecution's expert in Insys opioid bribe case

A federal judge on Wednesday ruled that prosecutors could not use a pain management specialist as an expert witness at next year's trial of several former Insys Therapeutics Inc executives accused of conspiring to bribe doctors to prescribe opioids.

Maryland charges Insys with engaging in deceptive opioid scheme

Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

UPDATE 2-Maryland charges Insys with engaging in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

Maryland charges Insys engaged in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with having engaged in deceptive practices that resulted in a powerful opioid medication the drugmaker produced that was meant for cancer patients being prescribed to other people.

Insys must face Aetna lawsuit alleging fraud over opioid -judge

A federal judge has rejected Insys Therapeutics Inc's bid to escape a lawsuit by Aetna Inc accusing the drugmaker of defrauding the insurer into paying claims for an opioid intended only for use by cancer patients that was prescribed for other purposes.

Opioid maker Insys in talks to settle New York lawsuit

Insys Therapeutics Inc is engaged in talks to settle a lawsuit by New York's attorney general seeking at least $75 million over allegations it recklessly promoted a fentanyl-based cancer pain medicine for much wider uses and bribed doctors to prescribe it.

REFILE-UPDATE 3-Insys to pay $150 mln to settle U.S. opioid kickback probe

Aug 8 Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Insys to pay $150 million to settle U.S. opioid kickback probe

Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Insys to pay $150 mln to settle DoJ probe

Aug 8 Insys Therapeutics said on Wednesday it had reached an agreement in principle with the U.S. Department of Justice to settle a civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.

FDA declines to approve Insys Therapeutic's opioid painkiller

Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

Select another date: